Download PDF
CC BY 4.0 · Endosc Int Open 2022; 10(10): E1331-E1332
DOI: 10.1055/a-1931-3841
Editorial

Follow-up after successful endoscopic therapy for early Barrett’s neoplasia: Is it time to talk money yet?

E. P.D. Verheij
1   Amsterdam UMC location University of Amsterdam, Gastroenterology and Hepatology, Amsterdam, The Netherlands
,
S. N. van Munster
1   Amsterdam UMC location University of Amsterdam, Gastroenterology and Hepatology, Amsterdam, The Netherlands
2   Sint Antonius Hospital, Gastroenterology and Hepatology, Nieuwegein, Netherlands
,
R. E. Pouw
1   Amsterdam UMC location University of Amsterdam, Gastroenterology and Hepatology, Amsterdam, The Netherlands
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Endoscopic eradication therapy (EET) using endoscopic resection followed by radiofrequency ablation (RFA) has proven to be a safe and highly effective treatment for patients with Barrett’s-related neoplasia. Recently, long-term follow-up studies have reported a low risk for development of neoplastic recurrences in patients who were successfully treated and achieved complete eradication of dysplasia and intestinal metaplasia (CE-IM) [1] [2]. This has put a new light on the discussion regarding surveillance protocols after EET. Currently, these surveillance protocols are based on expert opinion and derive from the era when endoscopic resection was performed with surveillance of the remaining Barrett’s esophagus (BE) segment, instead of pursuing complete eradication of all BE using RFA. The quest for the optimal surveillance protocol after successful EET is ongoing, and with the recent long-term follow-up studies, current strategies will likely be subject to change.



Publication History

Article published online:
17 October 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Refers to:

Comparative cost-effectiveness of three post-radiofrequency ablation surveillance intervals for Barrett’s esophagusEndosc Int Open 2022; 10(08): E1053-E1064
DOI: 10.1055/a-1858-0945

 

  • References

  • 1 van Munster S, Nieuwenhuis E, Weusten B. et al. Long-term outcomes after endoscopic treatment for Barrettʼs neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period. Gut 2022; 71: 265-276
    Google Scholar
  • 2 Wolfson P, Ho KMA, Wilson A. et al. Endoscopic eradication therapy for Barrett’s esophagus–related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry. Gastrointest Endosc 2022; 96: 223-233
    Google Scholar
  • 3 Menon S, Norman R, Mannath J. et al. Comparative cost effectiveness of three post radiofrequency ablation surveillance intervals for Barrett's oesophagus (BO). Endosc Int Open 2022; 10: E1053-E1064
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol 2016; 111: 30-50
    CrossrefPubMedGoogle Scholar
  • 5 Cotton CC, Haidry R, Thrift AP. et al. Development of evidence-based surveillance intervals after radiofrequency ablation of Barrett's esophagus. Gastroenterology 2018; 155: 316-26.e6
    Google Scholar
  • 6 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7
    CrossrefPubMedGoogle Scholar
  • 7 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut 2019; 68: 1379
    CrossrefPubMedGoogle Scholar
  • 8 van Munster S, Nieuwenhuis E, Bisschops R. et al. Dysplastic recurrence after successful treatment for early Barrettʼs neoplasia: development and validation of a prediction model. Gastroenterology 2022; 163: 285-294
    CrossrefPubMedGoogle Scholar
  • 9 Wani S, Han S, Kushnir V. et al. Recurrence is rare following complete eradication of intestinal metaplasia in patients with Barrett’s esophagus and peaks at 18 months. Clin Gastroenterol Hepatol 2020; 18: 2609-17.e2
    Google Scholar
  • 10 Wolf WA, Pasricha S, Cotton C. et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett’s esophagus. Gastroenterology 2015; 149: 1752-61.e1
    CrossrefPubMedGoogle Scholar